Is it possible to regrow cartilage? It is unclear whether the human body has the capacity to regrow cartilage after injury or even with normal joint wear during aging. In general, evidence for production of new cartilage after developmental maturation of joints is very limited. If regrowth does occur, it does not appear to be
Orthopedic indications are one of the most common reasons that people may seek or be directed to stem cell therapy. These include joint stiffness, instability, and pain associated with athletic injuries, repetitive use injuries, and osteoarthritis-related dysfunction. Do stem cells work on knees? The answer to this question is uncertain. Some patients treated with stem
Among the clinical applications considered for adult tissue stem cell therapy, relief of chronic pain is a major focus of investigation. The potential mechanisms for pain relief are not thought to be the tissue renewal properties of injected stem cells. Instead, the treatment basis is a hypothesis that tissue stem cells are able to produce
Asymmetrex’s AlphaSTEM Technology Is A First-Ever Technology For Quantitative Analysis Of Adult Tissue Stem Cells That Will Accelerate Progress In Stem Cell Biomedicine Click here to download a slide deck with the most recent technological benchmarks. Posted October 27, 2015 Overview Asymmetrex, LLC and AlphaSTAR Corporation (ASC) have partnered to develop a first-of-its-kind computer simulation-primary cell culture
The founder and director of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., continues to lead the company’s public service mission of disseminating timely scientific information on the qualities of tissue stem cells and their use for medical therapies. Most recently, in a July 20 invited essay posted on the Oncology webpage of
The founder and director of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., continues to lead the company’s campaign to educate the regenerative medicine community on its overdue implementation of new stem cell dose standardization technologies developed by his company. In a May 31 invited essay posted on the Operations webpage of ClinicalTrialsArena,
Although more investment by major pharmaceutical companies would accelerate progress in regenerative medicine, in recent years, regenerative medicine initiatives have experienced a tepid reception by Big Pharma. In an editorial article appearing today in Pharmaceutical Manufacturing, James Sherley, founder and director of stem cell biotechnology tools company Asymmetrex, offers an explanation and a solution for
Boston’s stem cell medicine biotechnology start-up Asymmetrex is beginning 2017 with exciting news for its recently launched contract service for counting adult tissue stem cells. The company’s webinar, produced with the international regenerative medicine social media network RegMedNet to describe Asymmetrex’s new counting technology and its applications, was 4th among the 10 most popular content
Today Asymmetrex continues its efforts to bring more attention to the long-standing need for tissue stem cell counting in regenerative medicine. In a post on RegMedNet, the company contrasts the quantitative dosing precision required for pharmaceutical drug trials to the complete vacuum of quantitative dosing for tissue stem cells in regenerative medicine trials. Asymmetrex invites
For Immediate Release Boston, MA (PRWEB) December 23, 2014 Adult Stem Cell Technology Center, LLC’s Director Sherley’s Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website This month a keynote address by Dr. James L. Sherley, Director of Boston’s Adult Stem Cell Technology Center, LLC, is featured on the website of the